We offer unparalleled expertise in developing generic pharmaceuticals and value added medicines and commercializing their innovation in the healthcare industry. We provide a broad portfolio of products and intellectual property to leading pharmaceutical companies.
OUR PHILOSOPHY
Developing Value
Supplying Success
Supplying Success
1
Our People
Our people are our core competitive advantage that helps us being one of the fastest growing pharmaceutical development companies in Europe.
2
Commitment to quality
At PharOS we meet pharmaceutical industry’s demanding requirements while ensuring the success of the most challenging projects.
3
Dedication
We work with an unwavering dedication to our people, clients, patients, safety & ethics.
LEADING AN EXCEPTIONAL TEAM
OF PROFESSIONALS
OF PROFESSIONALS
STELLA, THEODORE, PANAGIOTIS
PARTNERS
PARTNERS
For PharOS our customers, are our partners! Our aim is to extend the lifecycle of the product, as our people are able to provide an exceptional level of customer service and support, based on their expertise and professionalism. The boundaries of our business do not stop at European borders. We work with you globally across all geographic and cultural frontiers.
HISTORY TIMELINE
MANY YEARS OF UNPARALLELED EXPERIENCE
2002
Establishment of the company
2004
First project completed – 450 MAs granted simultaneously
2005
Started own development projects
2007
Among the first companies to run DCP via a fully compliant eCTD
Became founding member of the EuDRAcon®
2008
PharOS Polska Establishment
2009
First company to register
Exemestane in EU
Exemestane in EU
2010
First pan-EU registration of immunosuppressant block-buster
2011
First multinational approval of respiratory block-buster
2013
First Greek company to become member of Medicines for Europe (former EGA)
1st submission in USA
2015
EU GMP for Batch Release accredited
2019
GMP Certification of the PharOS MT Hal Far Manufacturing site
2020
Oncology Manufacturing Line in PharOS Malta
2024
RnD Lab Metamorfossi Athens HQs